Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MWA + Camrelizumab + Chemotherapy in Advanced NSCLC
NCT05532527Unknown
- Sponsor
- Henan Provincial People's Hospital
- Start
- Sep 2022
- Primary completion
- Sep 2023
- Modality
- Immune Checkpoint Inhibitors
01
Overview
Open-label, single-arm trial of camrelizumab in non-small cell lung cancer (NSCLC), sponsored by Henan Provincial People's Hospital. Primary endpoint: Progression-Free Survival at 24 months. Status: unknown.
02
Drugs
camrelizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05532527.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05532527.